$1.26 Billion is the total value of Ikarian Capital, LLC's 164 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMRN | Exit | AMARIN CORP PLCcall | $0 | – | -39,700 | -100.0% | -0.01% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS INput | $0 | – | -7,200 | -100.0% | -0.02% | – |
| DBVT | Exit | DBV TECHNOLOGIES S Aput | $0 | – | -52,800 | -100.0% | -0.02% | – |
| CMRX | Exit | CHIMERIX INC | $0 | – | -208,258 | -100.0% | -0.02% | – |
| MNKKQ | Exit | MALLINCKRODT PUB LTD CO | $0 | – | -194,322 | -100.0% | -0.03% | – |
| PGNX | Exit | PROGENICS PHARMACEUTICALS IN | $0 | – | -130,845 | -100.0% | -0.04% | – |
| KOD | Exit | KODIAK SCIENCES INCput | $0 | – | -11,800 | -100.0% | -0.04% | – |
| PFNX | Exit | PFENEX INC | $0 | – | -64,211 | -100.0% | -0.04% | – |
| NERV | Exit | MINERVA NEUROSCIENCES INC | $0 | – | -103,504 | -100.0% | -0.05% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -36,422 | -100.0% | -0.05% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -63,721 | -100.0% | -0.07% | – |
| SLDB | Exit | SOLID BIOSCIENCES INCcall | $0 | – | -449,800 | -100.0% | -0.08% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -158,222 | -100.0% | -0.08% | – |
| OVID | Exit | OVID THERAPEUTICS INC | $0 | – | -377,737 | -100.0% | -0.08% | – |
| CRTX | Exit | CORTEXYME INC | $0 | – | -25,000 | -100.0% | -0.09% | – |
| SAVA | Exit | CASSAVA SCIENCES INC | $0 | – | -300,000 | -100.0% | -0.09% | – |
| ALLK | Exit | ALLAKOS INCput | $0 | – | -30,000 | -100.0% | -0.10% | – |
| ALLK | Exit | ALLAKOS INCcall | $0 | – | -30,000 | -100.0% | -0.10% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INCcall | $0 | – | -84,100 | -100.0% | -0.10% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INCput | $0 | – | -100,000 | -100.0% | -0.11% | – |
| NXTC | Exit | NEXTCURE INCput | $0 | – | -40,700 | -100.0% | -0.11% | – |
| INO | Exit | INOVIO PHARMACEUTICALS INCput | $0 | – | -250,000 | -100.0% | -0.14% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -55,172 | -100.0% | -0.14% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -360,030 | -100.0% | -0.16% | – |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INCput | $0 | – | -150,000 | -100.0% | -0.17% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -184,989 | -100.0% | -0.17% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INC | $0 | – | -87,900 | -100.0% | -0.19% | – |
| ASND | Exit | ASCENDIS PHARMA A Sput | $0 | – | -70,000 | -100.0% | -0.28% | – |
| KALA | Exit | KALA PHARMACEUTICALS INC | $0 | – | -493,952 | -100.0% | -0.33% | – |
| CYTK | Exit | CYTOKINETICS INCput | $0 | – | -384,400 | -100.0% | -0.34% | – |
| INSM | Exit | INSMED INCcall | $0 | – | -300,000 | -100.0% | -0.36% | – |
| MYOK | Exit | MYOKARDIA INCcall | $0 | – | -113,400 | -100.0% | -0.40% | – |
| CYTK | Exit | CYTOKINETICS INCcall | $0 | – | -500,000 | -100.0% | -0.44% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCcall | $0 | – | -750,000 | -100.0% | -0.45% | – |
| CCXI | Exit | CHEMOCENTRYX INCcall | $0 | – | -150,000 | -100.0% | -0.45% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INCcall | $0 | – | -150,000 | -100.0% | -0.48% | – |
| GLPG | Exit | GALAPAGOS NVcall | $0 | – | -35,000 | -100.0% | -0.52% | – |
| MLND | Exit | MILLENDO THERAPEUTICS INCput | $0 | – | -1,403,900 | -100.0% | -0.56% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INCcall | $0 | – | -100,000 | -100.0% | -0.65% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INCput | $0 | – | -150,000 | -100.0% | -0.66% | – |
| ARGX | Exit | ARGENX SEcall | $0 | – | -75,000 | -100.0% | -0.74% | – |
| TARA | Exit | ARTARA THERAPEUTICS INC | $0 | – | -450,772 | -100.0% | -0.78% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INCput | $0 | – | -551,800 | -100.0% | -0.80% | – |
| ABBV | Exit | ABBVIE INCcall | $0 | – | -150,000 | -100.0% | -0.86% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INCput | $0 | – | -120,300 | -100.0% | -0.98% | – |
| LGND | Exit | LIGAND PHARMACEUTICALS INCcall | $0 | – | -200,000 | -100.0% | -1.09% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -150,000 | -100.0% | -1.29% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INCcall | $0 | – | -200,000 | -100.0% | -1.35% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -250,000 | -100.0% | -1.41% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -250,000 | -100.0% | -1.46% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -239,249 | -100.0% | -1.62% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INCcall | $0 | – | -246,900 | -100.0% | -2.02% | – |
| QQQ | Exit | INVESCO QQQ TRput | $0 | – | -550,000 | -100.0% | -2.22% | – |
| BIIB | Exit | BIOGEN INCcall | $0 | – | -143,400 | -100.0% | -3.41% | – |
| REGN | Exit | REGENERON PHARMACEUTICALSput | $0 | – | -130,000 | -100.0% | -4.77% | – |
| SPY | Exit | SPDR S&P 500 ETF TRcall | $0 | – | -250,000 | -100.0% | -4.85% | – |
| TLT | Exit | ISHARES TRput | $0 | – | -400,000 | -100.0% | -4.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.